Stivarga for osteosarcoma – pro
REGOBONE study reported in the Lancet showed that regorafenib demonstrated clinically meaningful antitumor activity in adult patients with recurrent, progressive, metastatic osteosarcoma after the failure of conventional chemotherapy, with a positive effect on delaying disease progression.
The SARCO24 met its primary endpoint, demonstrating activity of regorafenib in patients with progressive metastatic osteosarcoma. No new safety signals were observed. Regorafenib should be considered a treatment option for patients with relapsed metastatic osteosarcoma.
Florence Duffaud et al, Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet VOLUME 20, ISSUE 1, P120-133, JANUARY 01, 2019
Lara E. Davis et al, Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma, Clinical Oncology 37, no. 16 (June 01, 2019) 1424-1431.